Kenya - Inggeris - Pharmacy and Poisons Board

orange pharma ltd p.o.box: 39461 - 00623, nairobi - menthol (mentha piperita), camphor (cinnamomum… - inhalation vapour - menthol (mentha piperita): 42.5 w/w %, camphor… - other respiratory system products

Kenya - Inggeris - Pharmacy and Poisons Board

orange pharma limited p.o.box: 39461 - 00623, nairobi - menthol (mentha piperita) eucalyptus oil… - lozenge - menthol (mentha piperita) 0.34%w/w eucalyptus oil… - other respiratory system products

Kenya - Inggeris - Pharmacy and Poisons Board

the himalya drug company makali bangalore - 562 162 india - not applicable - tablet - 378 mg/ tablet - other respiratory system products

Kenya - Inggeris - Pharmacy and Poisons Board

orange pharma ltd p.o.box: 39461 - 00623, nairobi - menthol (mentha piperita), camphor (cinnamomum… - inhalation vapour - menthol (mentha piperita): 42.5 w/w %, camphor… - other respiratory system products

Singapura - Inggeris - HSA (Health Sciences Authority)

biomedical strategy consultants pte ltd - nitric oxide - gas - 800ppm

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystic fibrosis - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4.4 and 5.1).in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5.1).kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4.4 and 5.1).in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystic fibrosis - other respiratory system products - orkambi tablets are indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene.orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Kanada - Inggeris - Health Canada

ino therapeutics - nitric oxide - gas - 100ppm - nitric oxide 100ppm - nitrates and nitrites

Kanada - Inggeris - Health Canada

ino therapeutics - nitric oxide - gas - 800ppm - nitric oxide 800ppm - nitrates and nitrites

Kanada - Inggeris - Health Canada

airgas therapeutics llc - nitric oxide - gas - 100ppm - nitric oxide 100ppm - nitrates and nitrites